Clazakizumab

Clazakizumab is a monoclonal antibody with high affinity and specificity for the IL-6 (interleukin-6) cytokine. Clazakizumab may be helpful in inhibiting the cytokine response to SARS-CoV-2 in COVID-19. Clazakizumab can be used for the research of psoriatic arthritis (PsA) and renal antibody-mediated rejection[1][2].

Product Specifications

CAS Number

[1236278-28-6]

UNSPSC

12352203

Target

Interleukin Related; SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/clazakizumab.html

Purity

99.0

Solubility

H2O

Smiles

[Clazakizumab]

Molecular Weight

(145.234 kDa)

References & Citations

[1]Mease PJ, et al. The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis. Arthritis Rheumatol. 2016 Sep;68 (9) :2163-73.|[2]Vaidya G, et al. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Transplant Proc. 2020 Nov;52 (9) :2711-2714.